P299 EFFECTS OF SYMPTOM SEVERITY AT BASELINE ON LUNG-FUNCTION AND SGRQ RESPONSES IN THE OTEMTO® STUDIES

10.1136/thoraxjnl-2016-209333.478

FJ Martinez reports financial support from AstraZeneca, Affrent, Boehringer Ingelheim, ConCert, Genentech, GlaxoSmithKline, Kadmon, Mero, Pearl, Unity, Novartis, Takeda, Sunovion, Theravance and Veracyte for attendance at advisory boards, research support for steering committees from Affrent, Bayer, GlaxoSmithKline and Takeda, personal fees from UpToDate for a COPD CME programme, and financial support from Biogen and GlaxoSmithKline for participation in data safety monitoring boards.

R Abrahams reports grants and personal fees from Boehringer Ingelheim during the conduct of the study and, outside of this work, grants and personal fees from GlaxoSmithKline and grants from AstraZeneca and Pearl Therapeutics.

GT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingelheim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, AstraZeneca, Pearl Therapeutics and Sunovion, and grants from Forest.

L Bjermer reports no conflicts of interest.

L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

D Singh reports other financial activities from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, and personal fees from Genentech and SkyePharma.